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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects of probiotics to prevent the occurrence and reduce the severity of acute otitis media in children.
B A C K G R O U N D
Description of the condition
Acute otitis media (AOM) is one of the most common childhood
diseases. It is characterised by effusion of the middle ear and rapid
onset of symptoms such as ear pain, otorrhoea (discharge from
the ear), fever, and malaise (AAP 2013). Although AOM has low
mortality, it has high morbidity (Stool 1989); by two years of
age, 70% of children have had at least one episode of AOM, and
20% to 30% of children have experienced three or more episodes
(Hatakka 2007). Globally, the incidence rate of AOM is estimated
at 10.85% (the equivalent of 709million cases of AOMeach year);
the incidence rate varies, from a low of 3.64% in Central Europe
to 43.37% in central sub-Saharan Africa (Monasta 2012).
Clinical care guidelines for treatment of AOM vary internation-
ally. For mild-moderate cases, ’watchful waiting’ has now been
adopted in many high-income countries, although this remains
infrequent in low-income countries (Tamir 2017). Most guide-
lines recommend amoxicillin as first-line treatment, with some
exceptions: amoxicillin-clavulanate in some high-income coun-
tries, penicillin V in Scandinavian countries, and other first-line
treatments in low-income countries include trimethoprim-sul-
famethoxazole, cephalexin, cloxacillin, and others (Tamir 2017).
Although AOM is one of the main reasons for antibiotic prescrip-
tion in children (Hendley 2002), the rates of antibiotic prescrip-
tion for AOM vary internationally, from 56% of consultations
for AOM in the Netherlands, Akkerman 2005, to 95% in North
America (Froom 2001). However, using antibiotics in prophylaxis
and treatment of AOM leads to the development of antibiotic re-
sistance, and identification of alternatives to antibiotics for pre-
vention or treatment of AOM is becoming urgent (Cohen 2013;
Hatakka 2007; Niittynen 2012).
Description of the intervention
TheWorldHealthOrganization (WHO) defines probiotics as live
micro-organisms that confer a health benefit on the host when
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administered in adequate amounts (FAO-WHO 2006). Micro-
organisms used as probiotics include: Lactobacillus (e.g. L aci-
dophilus, L fermentum), Bifidobacterium (e.g. B bifidum, B lactis),
Streptococcus (e.g. S thermophiles) species, and Saccharomyces (e.g.
S boulardii) species (Niittynen 2012). Probiotics are available in
multiple forms: as tablets or powders (regulated as dietary supple-
ments), as a food ingredient (e.g. yogurts or kefirs) (Wang 2016),
or directly applied by spray to the throat (Roos 2001). Probiotics
are not currently part of clinical practice. Probiotics can be used
by adults and children (Wang 2016). In people with unimpaired
immune systems, probiotics do not have any known harmful ef-
fects (Marteau 2002).
How the intervention might work
Since otitis media is associated with colonisation by pathogenic
bacteria in the nasopharynx, and disruption of the balance of the
normal microbiota (Hatakka 2007), probiotics may act by restor-
ing the normal microbiota (i.e. by overwhelming the pathogens
with healthy commensals), rather than by attempting to kill
pathogens with antibiotics, although the mechanisms of any pro-
biotics benefit are unclear (Hao 2015). They may act by stabil-
ising gut microbiota; modulating immune function; competing
with pathogens for essential nutrients and adhesion sites on ep-
ithelial surfaces; producing bacteriocins or other inhibitory sub-
stances (Hao 2015; Hatakka 2007; Niittynen 2012).
Why it is important to do this review
Because antibiotic use leads to increased antibiotic resistance,
(O’Neill 2014), other options (including probiotics) are attracting
greater interest (Hatakka 2007). The most recent Cochrane Re-
view on the use of probiotics for preventing acute respiratory tract
infections did not include studies with AOMas an outcome on the
grounds that otitis-prone children may have immunodeficiencies
(Hao 2015). Several other Cochrane Reviews have investigated
other interventions for the prevention of otitis media. These in-
clude xylitol (Azarpazhooh 2016), pneumococcal conjugate vac-
cines (Fortanier 2014), influenza vaccines (Norhayati 2015), and
antibiotics (Leach 2013).
O B J E C T I V E S
To assess the effects of probiotics to prevent the occurrence and
reduce the severity of acute otitis media in children.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs), irrespective
of type (e.g. cluster, parallel, cross-over). We will include studies
reported as full text, those published as abstracts only, and unpub-
lished data.
Types of participants
We will include children (aged up to 18 years) diagnosed with
acute otitis media (AOM) by a clinician.
Wewill exclude children with the following comorbidities or char-
acteristics: chromosomal and genetic disorders; craniofacial ab-
normalities, including cleft palate; those taking systemic corticos-
teroids or with immune deficiency status; and those with cystic
fibrosis or primary ciliary dyskinesia.
Types of interventions
Wewill include trials comparing probiotics (including: Lactobacil-
lus spp, Bifidobacterium spp, Streptococcus spp, and Saccharomyces
spp) with placebo or usual care or lack of treatment. We will in-
clude probiotics of any composition (e.g. powder, drink, spray).
We will include studies that include a co-intervention (including
antibiotics) that is applied to both the intervention and control
groups, and we will perform a subgroup analysis for those studies.
Types of outcome measures
Primary outcomes
1. Incidence of AOM.
2. Severity of AOM.
3. Adverse events (e.g. gastrointestinal side effects).
Secondary outcomes
1. Median duration of AOM episodes (days).
2. Difference between probiotic and non-probiotic groups in
use of antibiotics to treat AOM (e.g. dose, duration)
3. Time off school (for the child) (e.g. in days or hours)
4. Time off work (for the parent or carer) (e.g. in days or
hours)
5. Difference between probiotic and non-probiotic groups in
hearing loss, if AOM occurs.
6. Serous/secretory otitis media.
7. Reduction in referrals to a specialist (e.g. for glue ear).
8. Reduction in other infections (respiratory and
gastrointestinal).
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9. Compliance with taking probiotics (e.g. measured by pill
count or weight of the spray bottle).
10. Quality of life measures (using any validated quality of life
measure).
11. Difference in use of other treatments (e.g. differences in
dosage of analgesics, decongestants).
Search methods for identification of studies
Electronic searches
We will search the following databases from inception to present.
• Cochrane Acute Respiratory Infections Group Specialized
Register
• CENTRAL (Cochrane Central Register of Controlled
Trials)
• MEDLINE (PubMed)
• Embase
• CINAHL (Cumulative Index to Nursing and Allied Health
Literature)
• Web of Science
• LILACS (Latin American and Caribbean Health Sciences
Literature database)
We will use the search strategy described in Appendix 1 to search
PubMed. We will combine the PubMed search with the Cochrane
Highly Sensitive Search Strategy for randomised trials: sensitiv-
ity and precision-maximising version (2008 revision) (Lefebvre
2011).We will not impose any language, publication date, or pub-
lication status restrictions. We will convert the search for use in
the other databases.
We will also conduct a search of ClinicalTrials.gov (
www.clinicaltrials.gov) and the WHO International Clinical Tri-
als Registry Platform ( apps.who.int/trialsearch/) to identify pub-
lished registered trials, as well as ongoing studies.
Where relevant, for completed trials that appear to be unpublished,
we will contact trial investigators for unpublished data.
Wewill run backward (cited) and forward (citing) citation analyses
for all included studies. We will also use the similar article feature
in PubMed and the shared citation matcher in Web of Science to
identify any potential trials missed by the search strategy.
Searching other resources
We will contact experts in the field to identify additional unpub-
lished materials.
Data collection and analysis
Selection of studies
Two review authors (AMS, JC) will independently screen titles
and abstracts for inclusion of all the potential studies we identify
as a result of the search.
We will retrieve the full-text study reports/publication, and two
review authors (AMS, JC) will independently screen the full text
and identify studies for inclusion, and identify and record reasons
for exclusion of the ineligible studies. Any disagreements will be
resolved through discussion or by consulting a third review author
(CDM) when necessary. We will identify and exclude duplicates
and collate multiple reports of the same study so that each study
rather than each report is the unit of interest in the review. We
will record the selection process in sufficient detail to complete a
PRISMA flow diagram and ’Characteristics of excluded studies’
table (Moher 2009).We will not impose any language restrictions.
Data extraction and management
We will use a data collection form for study characteristics and
outcome data that has been piloted on at least one study in the
review. Two review authors (AMS, JC) will extract the following
study characteristics from included studies.
1. Methods: study location, study design, study objective,
study duration
2. Participants: N, type of participants, mean age, age range,
gender, comorbidities, number of previous episodes of otitis
media, diagnostic criteria
3. Interventions: probiotic type, duration, dose, comparison,
other permitted interventions (e.g. concomitant analgesics,
decongestants), other prohibited interventions (e.g. analgesics,
decongestants)
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported
5. Notes: funding for trial, and notable conflicts of interest of
trial authors
Two review authors (AMS, JC)will independently extract outcome
data from the included studies. We will note in the ’Characteristics
of included studies’ table if outcome data are not reported in a
useable way. Any disagreements will be resolved by consensus or
by involving a third review author (CDM). One review author
(EB) will transfer data into the Review Manager 5 file (RevMan
2014). We will double-check that data are entered correctly by
comparing the data presented in the systematic review with the
study reports. A second review author (CDM) will spot-check
study characteristics for accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors (AMS, JC) will independently assess risk of
bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Any disagreements will be resolved by discussion or by involving
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another review author (EB, CDM). We will assess the risk of bias
according to the following domains.
1. Random sequence generation
2. Allocation concealment
3. Blinding of participants and personnel
4. Blinding of outcome assessment
5. Incomplete outcome data
6. Selective outcome reporting
7. Other bias
We will grade each potential source of bias as high, low, or un-
clear and provide a quote from the study report together with a
justification for our judgement in the ’Risk of bias’ table. We will
summarise the ’Risk of bias’ judgements across different studies
for each of the domains listed. Where necessary, we will consider
blinding separately for different key outcomes. Where informa-
tion on risk of bias relates to unpublished data or correspondence
with a trialist, we will note this in the ’Risk of bias’ table.
When considering treatment effects, we will take into account the
risk of bias for the studies that contribute to that outcome.
Assessment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and report any deviations from it in the ’Differences between pro-
tocol and review’ section of the systematic review.
Measures of treatment effect
We will enter the outcome data for each study into the data tables
in Review Manager 5 to calculate the treatment effects (RevMan
2014). We will use risk ratios for dichotomous outcomes, rate
ratios for outcomes measured as rates (e.g. adverse events), and
mean differences or standardised mean differences for continuous
outcomes.
We will undertake meta-analyses only where this is meaningful,
that is if the treatments, participants, and the underlying clinical
question are similar enough for pooling to make sense. If meta-
analysis is possible, we will use a random-effects model for high
heterogeneity and a fixed-effect model for low heterogeneity.
Unit of analysis issues
We will use the participant as the unit of analysis, except for any
cluster RCTs.
Dealing with missing data
We will contact investigators or study sponsors to verify key study
characteristics and obtain missing numerical outcome data where
possible (e.g. when a study is identified as abstract only). Where
this is not possible, and the missing data are thought to introduce
serious bias, we will explore the impact of including such studies
in the overall assessment of results by a sensitivity analysis.
If numerical outcome data such as standard deviations or correla-
tion coefficients are missing, and they cannot be obtained from the
authors, we will calculate them from other available statistics such
as P values according to the methods described in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Assessment of heterogeneity
We will use the I² statistic to measure heterogeneity among the
trials in each analysis. If we identify substantial heterogeneity, we
will report it and explore possible causes by prespecified subgroup
analysis. We will consider an I² statistic value of 0% to 40% to be
low heterogeneity, 41% to 60% as moderate heterogeneity, 61%
to 90% substantial heterogeneity, and over 91% to be considerable
heterogeneity (Higgins 2011).
Assessment of reporting biases
If we are able to pool more than 10 trials, we will create and exam-
ine a funnel plot to explore possible small-study and publication
biases.
Data synthesis
We will pool data from studies we judge to be clinically homoge-
neous using Review Manager 5 software (RevMan 2014). If more
than one study provides useable data in any single comparison, we
will perform a meta-analysis. As sizeable heterogeneity is expected
in terms of populations, probiotics studied, etc., we will use the
random-effects model. If an insufficient volume of evidence exists
to perform a meta-analysis, we will report outcomes in a narrative
format.
GRADE and ’Summary of findings’ table
We will create a ’Summary of findings’ table using the following
outcomes: incidence of AOM, severity of AOM, adverse events,
median duration of AOM episodes, difference between groups in
antibiotic use, time off school (child), time off work (parent or
carer). We will use the five GRADE considerations (study limita-
tions, consistency of effect, imprecision, indirectness, and publi-
cation bias) to assess the quality of a body of evidence as it relates
to the studies that contribute data to the meta-analyses for the
prespecified outcomes (Atkins 2004). We will use methods and
recommendations described in Section 8.5 and Chapter 12 of the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011), employing GRADEproGDT software (GRADEproGDT
2014).We will justify all decisions to down- or upgrade the quality
of studies using footnotes, and we will make comments to aid the
reader’s understanding of the review where necessary.
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Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses.
1. Child’s age (≤ two years: see Rovers 2006)
2. Type of probiotic
3. Children with severe AOM (fever > 39 °C; bilateral otitis;
or perforation of the tympanic membrane, see Rovers 2006)
4. Studies that include a co-intervention (including
antibiotics) that is applied to both the intervention and control
groups
Wewill use theChi² test to test for subgroup interactions inReview
Manager 5 (RevMan 2014).
Sensitivity analysis
We plan to carry out the following sensitivity analysis.
1. Including versus excluding studies with two or more
domains rated as at high risk of bias
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A P P E N D I C E S
Appendix 1. PubMed (National Library of Medicine) search strategy
(Probiotics[Mesh]OR “Synbiotics”[Mesh]ORLactobacillus[Mesh]ORBifidobacterium[Mesh]ORSaccharomyces[Mesh]OR “Strep-
tococcus thermophilus”[Mesh] OR “Cultured Milk Products”[Mesh] OR Antibiosis[Mesh] OR “Lactococcus”[Mesh] OR Probi-
otics[tiab] OR Probiotic[tiab] OR Synbiotics[tiab] OR Synbiotic[tiab] OR Lactobacillus[tiab] OR Lactobacilli[tiab] OR Bifidobacte-
ria[tiab] OR Bifidobacterium[tiab] OR Saccharomyces[tiab] OR Saccharomyce[tiab] OR “Microbial dietary supplements”[tiab] OR
Yoghurt[tiab] OR “Fermented milk”[tiab] OR “Cultured Milk”[tiab] OR “Fermented Dairy”[tiab] OR Acidophilus[tiab] OR An-
tibiosis[tiab] OR “Microbial Antagonism”[tiab] OR “Microbial Antagonisms”[tiab] OR “Bacterial Interferences”[tiab] OR “Bacterial
Interference”[tiab] OR “Streptococcus thermophilus”[tiab] OR “Bacillus laterosporus”[tiab] OR “Pediococcus acidilactici”[tiab] OR
Lactococcus[tiab] OR Lactis[tiab])
AND
(“Respiratory Tract Infections”[Mesh] OR “Respiratory tract infection”[tiab] OR “Respiratory tract infections”[tiab] OR “Respiratory
infection”[tiab] OR “Respiratory infections”[tiab] OR urti[tiab] OR uri[tiab] OR ari[tiab] OR “Otitis Media”[Mesh] OR “Otitis
Media”[tiab] OR “Glue ear”[tiab] OR AOM[tiab] OROME[tiab] OR (“Middle Ear”[tiab] AND (Infection[tiab] OR Infections[tiab]
OR Inflammation[tiab] OR Inflammations[tiab])))
AND
((Randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR randomised[tiab] OR placebo[tiab] OR
“drug therapy”[sh] OR randomly[tiab] OR trial[tiab] OR groups[tiab])
NOT (Animals[Mesh] not (Animals[Mesh] and Humans[Mesh])))
C O N T R I B U T I O N S O F A U T H O R S
Draft the protocol: AMS, KG, EB, KR, JC, PL, CDM
Develop the search strategy: JC
Run the search strategy: JC
Obtain copies of studies: JC
Select which studies to include: AMS, JC
Extract data from studies: AMS, JC
Enter data into Review Manager 5: AMS, JC, EB
Carry out the analysis: EB
Interpret the analysis: AMS, KG, EB, KR, JC, PL, CDM
Draft the final review: AMS, KG, EB, KR, JC, PL, CDM
Check correct use of grammar: CDM
Update the review: AMS, CDM
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Elaine Beller: This review was supported in part by research grants from the NHMRC, Australia, to the Centre for Evidence-Based
Practice, Bond University.
JustinClark: Salary funded by theCentre for Research Excellence inMinimisingAntibiotic Resistance fromAcute Respiratory Infections
(CREMARA), which itself is funded by the National Health and Medical Research Council (NHMRC), Australia.
Kristian Roos: I am a minor shareholder of a small biomedical company (ESSUM AB). This company has been doing research for
many years with probiotic bacteria. ESSUM AB has no patent in probiotic bacteria that might be used for acute otitis media, and
ESSUM has no intention of doing research into acute otitis media.
Keith Grimwood: None known.
Paul Little: A study PL was Chief Investigator for, had placebo and probiotic tablets provided by a commercial company that makes
probiotic (Cultech).
Chris Del Mar: reports CREMARA institutional funding (NHMRC); Cochrane Acute Respiratory Infections Group institutional
funding (NHMRC); institutional and personal funding from the Australian Commission on Safety and Quality in Health Care for the
development of patient decision aids; personal consulting funding for shared decision-making implementation (BUPA, UK); American
College of Physicians (ACP) Journal Club editorial work; consultancy/providing advice to a pharmaceutical company about a proposed
vaccine that might be effective against otitis media in children.
S O U R C E S O F S U P P O R T
Internal sources
• There are no internal sources of support to report., Other.
External sources
• There are no external sources of support to report., Other.
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